(274 days)
Not Found
No
The device description and performance studies focus on the material properties and biocompatibility of a bone graft substitute, with no mention of AI or ML technology.
Yes.
The device is intended for use in dental surgery for various augmentation and reconstructive treatments of bone defects, which constitutes a therapeutic purpose.
No
The device description clearly states that these products are "natural, porous bone mineral matrices with and without collagen" intended for use as "bone graft substitutes" in various dental surgical procedures for augmentation, filling defects, and preservation of the alveolar ridge. This describes a therapeutic or reconstructive device, not a diagnostic one.
No
The device description clearly states the product is a "natural, porous bone mineral matrix with and without collagen," supplied in "granules or blocks." This indicates a physical, material-based device, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is for use in "dental surgery" for procedures like bone grafting and filling defects. This is a surgical intervention performed directly on the patient's body.
- Device Description: The description details a "natural, porous bone mineral matrix" derived from bovine bone, used as a bone graft substitute. This is a material implanted into the body.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, urine, tissue samples) to provide information for diagnosis, monitoring, or screening.
IVD devices are used in vitro (outside the body) to analyze samples and provide diagnostic information. This device is used in vivo (inside the body) as a surgical implant.
N/A
Intended Use / Indications for Use
OsteoGuide Anorganic Bone Mineral Products are intended for use in dental surgery. The products may be used in surgical procedures such as:
- Augmentation or reconstructive treatment of alveolar ridge ●
- . Filling of periodontal defects
- Filling of defects after root resection, apicocectomy, and cystectomy ●
- Filling of extraction sockets to enhance preservation of the alveolar ridge .
- Elevation of maxillary sinus floor .
- Filling of periodontal defects in conjunction with products intended for Guided . Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR)
- Filling of peri-implant defects in conjunction with products intended for Guided . Bone Regeneration
Product codes
NPM
Device Description
"OsteoGuide™ Anorganic Bone Mineral," "OsteoGuide Collagen™ Anorganic Bone Mineral with Collagen,"and "OsteoGuide Blocks™ Anorganic Bone Mineral with Collagen Blocks" are natural, porous bone mineral matrices with and without collagen. The anorganic bone mineral is produced by removal of all organic components from bovine bone. Due to its natural structure, the anorganic bone mineral component of the OsteoGuide products is physically and chemically comparable to the mineralized matrix of human bone. The composition of OsteoGuide Anorganic Bone Mineral meets the requirements of ASTM F1581-99 Standard Specification for Composition of Anorganic bone for Surgical Implants. OsteoGuide Collagen and OsteoGuide Blocks are product extensions that include highly purified fibrillar type I collagen mixed in with the anorganic bone mineral. The product is supplied in granules or blocks, and it is sterile, non-pyrogenic, and for single use only.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The device passed all selected FDA Blue Book Memorandum G95-1and ISO 10993-1 testing for the biological evaluation of medical devices. The characteristics of the OsteoGuide Anorganic Bone Mineral Products meet the design requirements for an effective bone grafting material.
Key Metrics
Not Found
Predicate Device(s)
Bio-Oss®, Bio-Oss® Blocks, Bio-Oss® Collagen, K033815, Bio-Oss® Granules, K952617, Bio-Oss® Blocks, K970569, Bio-Oss® Collagen, K974399
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 872.3930 Bone grafting material.
(a)
Identification. Bone grafting material is a material such as hydroxyapatite, tricalcium phosphate, polylactic and polyglycolic acids, or collagen, that is intended to fill, augment, or reconstruct periodontal or bony defects of the oral and maxillofacial region.(b)
Classification. (1) Class II (special controls) for bone grafting materials that do not contain a drug that is a therapeutic biologic. The special control is FDA's “Class II Special Controls Guidance Document: Dental Bone Grafting Material Devices.” (See § 872.1(e) for the availability of this guidance document.)(2) Class III (premarket approval) for bone grafting materials that contain a drug that is a therapeutic biologic. Bone grafting materials that contain a drug that is a therapeutic biologic, such as biological response modifiers, require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
- AUG 4 2005
K043034
510(k) Summary of Safety and Effectiveness
| Applicant Name and Address: Collagen Matrix, Inc. | 509 Commerce Street
Franklin Lakes, New Jersey 07417 |
|---------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Peggy Hansen, RAC
Director, Clinical, Regulatory, and Quality Assurance
Tel: (201) 405-1477
Fax: (201) 405-1355 |
| Date of Summary: | February 17, 2005 |
| Device Common Name: | Bone Grafting Material |
| Device Trade Name: | OsteoGuide™ Anorganic Bone Mineral
OsteoGuide Collagen™ Anorganic Bone Mineral with
Collagen
OsteoGuide Blocks™ Anorganic Bone Mineral with
Collagen Blocks |
| Device Classification Name: | Bone Grafting Material
Unclassified
NPM |
| Predicate Device(s): | Bio-Oss®, Bio-Oss® Blocks, Bio-Oss® Collagen, K033815
Bio-Oss® Granules, K952617
Bio-Oss® Blocks, K970569
Bio-Oss® Collagen, K974399 |
Description of the Device
"OsteoGuide™ Anorganic Bone Mineral," "OsteoGuide Collagen™ Anorganic Bone Mineral with Collagen,"and "OsteoGuide Blocks™ Anorganic Bone Mineral with Collagen Blocks" are natural, porous bone mineral matrices with and without collagen. The anorganic bone mineral is produced by removal of all organic components from bovine bone. Due to its natural structure, the anorganic bone mineral component of the OsteoGuide products is physically and chemically comparable to the mineralized matrix of human bone. The composition of OsteoGuide Anorganic Bone Mineral meets the requirements of ASTM F1581-99 Standard Specification for Composition of Anorganic bone for Surgical Implants. OsteoGuide Collagen and OsteoGuide Blocks are product extensions that include highly purified fibrillar type I collagen mixed in with the anorganic bone mineral. The product is supplied in granules or blocks, and it is sterile, non-pyrogenic, and for single use only.
1
Intended Use
OsteoGuide Anorganic Bone Mineral Products are intended for use in dental surgery. The products may be used in surgical procedures such as:
- Augmentation or reconstructive treatment of alveolar ridge ●
- . Filling of periodontal defects
- Filling of defects after root resection, apicocectomy, and cystectomy ●
- Filling of extraction sockets to enhance preservation of the alveolar ridge .
- Elevation of maxillary sinus floor .
- Filling of periodontal defects in conjunction with products intended for Guided . Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR)
- Filling of peri-implant defects in conjunction with products intended for Guided . Bone Regeneration
Summary/Comparison of Technical Characteristics
OsteoGuide Anorganic Bone Mineral Products and their predicates have the same technological characteristics. In particular, the OsteoGuide Anorganic Bone Mineral Products and their predicates are the same with respect to intended use, material, material characterization, form, and sizes.
Safety
OsteoGuide Anorganic Bone Mineral Products have been evaluated by a number of tests to assess its safety/biocompatibility. The device passed all selected FDA Blue Book Memorandum G95-1and ISO 10993-1 testing for the biological evaluation of medical devices.
Effectiveness
The characteristics of the OsteoGuide Anorganic Bone Mineral Products meet the design requirements for an effective bone grafting material.
Conclusion
The results of the in vitro product characterization studies, in vitro and in vivo biocompatibility studies, show that the OsteoGuide Anorganic Bone Mineral Products are safe and substantially equivalent to Bio-Oss Granules, Bio-Oss Collagen, and Bio-Oss Blocks.
2
Image /page/2/Picture/1 description: The image shows the seal of the Department of Health and Human Services, USA. The seal features a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH AND HUMAN SERVICES, USA" are arranged in a circular pattern around the eagle. The eagle is depicted in a simple, black and white design.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
AUG 4 - 2005
Ms. Peggy Hansen Director, RAC Collagen Matrix, Incorporated 509 Commerce Street Franklin Lakes, New Jersey 07417
Re: K043034
Trade/Device Name: Osteoguide Anorganic Bone Mineral Products Regulation Number: 21 CFR 872.3930 Regulation Name: Tricalcium phosphate granules for dental bone repair Regulatory Class: II Product Code: NPM Dated: July 21, 2005 Received: July 22, 2005
Dear Ms. Hansen:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
3
Page 2 - Ms. Hansen
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Chiu Lin, Ph.D.
Director Division of Anesthesiology, General Hospital Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4